Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. - Wikidata - wikimedia - TriplyDB

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

http://www.wikidata.org/entity/Q34283903

about

Systems pharmacology: network analysis to identify multiscale mechanisms of drug action Pharmacogenetics and anaesthesia: the value of genetic profiling Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Warfarin Pharmacogenetics: New Life for an Old Drug A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug Genetic variability in CYP3A5 and its possible consequences.Integration of genetic, clinical, and INR data to refine warfarin dosing.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.Warfarin therapy: in need of improvement after all these years.Pharmacogenetics of warfarin: challenges and opportunities.The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.Implementing genotype-guided antithrombotic therapy.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Pharmacogenomics: a systems approach.Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.BDDCS applied to over 900 drugs.Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.Common VKORC1 and GGCX polymorphisms associated with warfarin dose.The future prospects of pharmacogenetics in oral anticoagulation therapy.Warfarin toxicity and individual variability-clinical case.Association of warfarin dose with genes involved in its action and metabolism.Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.Combinatorial pharmacogenetics.Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.Process map proposal for the validation of genomic biomarkers.Pharmacogenetics of warfarin: current status and future challenges.A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.Impact of genetic variation on perioperative bleeding.Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Genomics: risk and outcomes in cardiac surgery Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

P2860

Q26824166-777F84FD-6C78-40E3-B6F5-CE8A15984534 Q26859221-75A65F08-39D3-4138-9E15-F1FAE1C3ED28 Q27002899-1576A30D-F00D-4B28-AF62-D266E72CDF32 Q28083875-43E8394D-4449-4192-A7DC-C72884A8FCDB Q28276514-B2A3FC75-E4B6-4106-8CBC-F00A4F7A251A Q28468726-20CBCA3B-EF07-45C1-B54E-BD894ADA433F Q28475004-EF9A1403-C593-47FE-880E-ADC27151F855 Q28544111-B440C854-0188-45BD-8DFF-D35600C820E8 Q30341330-477A79D6-85C3-4203-9C6C-98BB2593BD37 Q33550741-4CBB8374-EE46-458F-BB42-2A50B219E573 Q33770184-48E47333-2116-45F0-9538-396D9A8E2497 Q33792352-30DEC958-9F0B-4C5F-A9FC-A751ED1D24B9 Q33793086-4D3C4DAC-D91B-4E85-B144-11334B62F35E Q33819050-A1D92AB2-99B8-4E4A-B2ED-1A54B4CA75DA Q33929926-8F656F58-88C2-4559-9E3F-E132C0015378 Q33990428-7B52312D-992C-4F75-A851-727008B4B137 Q33990441-B90BC161-1C77-4366-B6E6-77A2EFE49F38 Q34065133-6D85C5FE-5579-4CF0-BC44-C059601415E3 Q34137575-3C476856-9FFC-49AA-A6ED-C31DA2F01F40 Q34146486-2A14449A-B15A-4583-80C8-B07FD320ABCB Q34206152-21F419ED-A5DC-42E3-A2C6-431AC9E28DDB Q34348637-0FA367CD-B8F7-47EC-BF46-B4B3C2700EE9 Q34417386-24BB85C1-8F71-49AD-934D-9E5C8A8FBDA3 Q34530230-3339B08C-2945-452A-BEE8-BE20727DDCED Q35155651-030EA4D3-BD98-4CDB-BA0D-8DC4C3F8B1B0 Q35633802-80FAA8FE-8EA1-4C50-B96D-4B24C9799B64 Q35681000-D1471BD5-1FA0-490A-AA4D-552ADB36AD94 Q35900767-473EFB3A-7AAC-4039-A44E-277D1EAE57AC Q36044022-5FCB7C98-19BB-4260-B1B1-9854666A4939 Q36120816-66169756-8780-4638-A62B-E2E2D0D3AED1 Q36303810-0831F97B-45BD-4876-B280-60CBBB50B2F9 Q36545011-55FA7282-697B-493D-91E7-874C1590486F Q36555934-3273EFAF-7B61-4355-8B1E-0AE1920A9BBD Q36597343-9E8EA5D9-8F3D-4CA0-8E43-195670E7A285 Q37087333-9242B45D-F453-47ED-B8AD-3439D13F5A21 Q37087348-E137476F-CC65-4786-80B5-798ADB70CEB3 Q37174998-00CB5497-7944-4AEE-A96C-41340865CF9D Q37264555-622D603A-E213-41E6-834D-29FB67B3577B Q37347806-B2759244-7520-4CE0-883C-98F4EA51400D Q37372721-535F3EB6-CA71-47B0-A5DB-8FCCE3767849

P2860

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

http://www.wikidata.org/entity/Q34283903

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@ast

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@en

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@nl

type

label

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@ast

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@en

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@nl

prefLabel

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@ast

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@en

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

@nl

P1433

Q34283903-762309C9-A3E8-4E15-83B2-A0CE32F4B134

P1476

Q34283903-E8D5B9AF-6E28-4DC7-A30C-6190D586C12C

P2093

Q34283903-7462068C-9C2E-4F73-9213-F1EB1AC60F47

Q34283903-A72D79D3-B5CC-46F4-AE38-CD95739AA922

Q34283903-BF921361-3E1A-4C3B-9042-DC052872CBC0

Q34283903-D73E02CA-D05E-4F49-BDB6-4633E336D39A

Q34283903-E07C4484-0687-48EC-8876-80F48C7A8288

Q34283903-E6CFA907-A63A-4A2C-884C-93880691FE67

P2860

Q34283903-12916320-978B-4AED-91DB-A979F98433BF

Q34283903-33B81BDE-C68D-4F45-9F32-C3268FADF27C

Q34283903-49680C16-4A80-4254-85FF-EA122D00D457

Q34283903-53DD5DAA-2306-4733-904D-712089B88B08

Q34283903-619B72DA-767A-4FB0-956F-D14F386B5A66

Q34283903-6FA8B10B-DF1A-467B-9F0B-E9E2BD7CCF5E

Q34283903-78720A10-4239-4B9C-ACA1-C58F0D482DF3

Q34283903-80D40B48-8FFD-4744-8E69-6B0F1AD7CA70

Q34283903-85E421FE-BE0B-4DBE-ADB2-46814B2D6430

Q34283903-89C74A4D-36A7-4343-827F-C020DEC8AFF4

P2888

Q34283903-82919181-E97E-4896-AE13-ED428102ACE7

P304

Q34283903-4BECE40B-7469-4862-9FF4-B026C416BF49

P31

Q34283903-02A37CCF-89C2-4AAE-95B3-7CF2416E19AA

P356

Q34283903-4FBE09E5-4D28-4452-BF61-E4F54737F68F

P433

Q34283903-2129E041-DC80-43A2-8A64-101C5B1B3980

P478

Q34283903-0BEFD24B-1E78-4C9B-93C0-8B22EB5C52E6

P50

Q34283903-A30EAF5A-FABC-43F3-B0E2-0BD3FDC4109A

Q34283903-B72A89CB-F61C-402A-A794-B47FF72F63C5

P577

Q34283903-0C617F24-9E42-4889-A8D6-CC62A8A8FB87

P5875

Q34283903-70D4EDB1-E12C-414E-8A8B-990E470E7EBA

P6179

Q34283903-61D39C2B-F812-40D3-81AD-F9BA36D9BE18

P698

Q34283903-A83C1DD1-BAB4-4DB5-AF11-FE03F5FC112A

P356

P1433

The Pharmacogenomics Journal

P1476

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors

@en

P2093

Karlsson J

http://www.w3.org/2001/XMLSchema#string

Melhus H

http://www.w3.org/2001/XMLSchema#string

Sörlin K

http://www.w3.org/2001/XMLSchema#string

Wadelius C

http://www.w3.org/2001/XMLSchema#string

Wadelius M

http://www.w3.org/2001/XMLSchema#string

Yue QY

http://www.w3.org/2001/XMLSchema#string

P2860

A New Statistical Method for Haplotype Reconstruction from Population Data

A sequencing method based on real-time pyrophosphate

Pharmacogenetics of oral anticoagulants.

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin.

Polymorphisms in the ABC drug transporter gene MDR1.

Clinically important drug interactions with anticoagulants. An update.

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

Interactions of warfarin with drugs and food.

P2888

P304

40-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.TPJ.6500220

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Patrik K E Magnusson

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8958060

http://www.w3.org/2001/XMLSchema#string

P6179

1052611133

http://www.w3.org/2001/XMLSchema#string

P698

14676821

http://www.w3.org/2001/XMLSchema#string